A prospective, multicenter, randomized and parallel control study on avoid recurrence in adenomyoma after conservative surgery using Triptorelin Acetate

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014340

Enrollment

Unknown

Registered

2018-01-06

Start date

2018-01-08

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyoma

Interventions

Group A:Blank

Group B:GnRHa 3.75mg

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Pathological and clinical diagnosis indicate adenomyoma; women aged 18-40 years; with no steroid hormone treatment 3 months before surgery; healthy and non-pregnancy; be volunroy to this trial and sign consent form.

Exclusion criteria

Exclusion criteria: Participating in other clinical trials; with ovarian endometrioma or deep infiltration endometriosis or multiple uterus leiomyoma; steroid hormone treatment within 3 months before surgery; with anaemia caused by disorder in hematological system, liver and renal function and nutrition; can not tolerate surgery and medical treatment; unsilling to sign informed consent; unwilling to obey requirements of the research.

Design outcomes

Primary

Measure	Time frame
size of uterus;size of adenomyoma;	—

Secondary

Measure	Time frame
FSH;estrogen;AMH;CA125;	—

Countries

China

Contacts

Public ContactWang Shixuan

Huazhong University of Science and Technology

shixuanwang@126.com+86 13995553319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026